Keytruda SC with Alteogen’s ALT-B4 Receives Sales Approval in Japan
MSD Secures Approval for Subcutaneous Formulation of Keytruda in Japan
Same Cancer Indications as Existing IV Injection
Following the US, Europe, and Canada, Japan Approves ALT-B4-Based Product, Expanding Commercialization
Alteogen announced on September 18 that MSD's Keytruda SC (marketed as Keyject in Japan), a subcutaneous injection (SC) formulation that uses Alteogen's proprietary formulation change platform Hybrozyme and its core ingredient ALT-B4 (ingredient name: berahyaluronidase alpha), has received manufacturing and sales approval in Japan.
Keytruda SC is a combination product that applies Alteogen's berahyaluronidase alpha to MSD's immunotherapy Keytruda (ingredient name: pembrolizumab), enabling the existing intravenous (IV) formulation of Keytruda to be administered subcutaneously.
With this approval, Keytruda SC can now also be used in Japan. While the conventional IV formulation is administered intravenously over approximately 30 minutes, the SC formulation can be administered in just one to two minutes.
After securing approvals in the United States, Europe, and Canada, Keytruda SC has now received authorization in Japan as well, thereby expanding its commercial reach in major markets. Alteogen explained that ALT-B4 is a recombinant human hyaluronidase that temporarily degrades hyaluronic acid under the skin, facilitating the spread and absorption of the drug in subcutaneous tissue.
In August, Alteogen disclosed that it would receive a first sales milestone payment of USD 25 million (approximately KRW 34.5 billion) from MSD following the launch of Keytruda SC. This is the first of Keytruda SC's sales milestones covered under the licensing agreement between the two companies, which could total up to USD 1 billion (approximately KRW 1.38 trillion).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This approval in Japan is based on phase 3 clinical trial MK-3475A-D77, conducted in patients with advanced or recurrent non-small cell lung cancer. In this trial, the SC formulation of Keytruda combination therapy was compared to the IV formulation, and non-inferiority of the SC formulation was confirmed. No new safety concerns were identified compared to the existing IV formulation, and MSD stated that the safety profile of the SC formulation was consistent with previous treatments.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.